Search Results

Natalizumab: new measures to manage PML

• Source: WHO Drug Information. Wntr, 2016, Vol. 30 Issue 1, p49, 2 p.

Record details

Natalizumab: no definite link with melanoma

• Source: WHO Drug Information. Spring, 2015, Vol. 29 Issue 2, p148, 2 p.

Record details

Natalizumab: progressive multi-focal leukoencephalopathy

• Source: WHO Drug Information. Wntr, 2012, Vol. 26 Issue 1, p32, 2 p.

Record details

Resumed marketing of natalizumab

• Source: WHO Drug Information. Spring, 2006, Vol. 20 Issue 2, p90, 1 p.

Record details

Natalizumab for moderate-to-severe Crohn disease

• Source: WHO Drug Information. Wntr, 2008, Vol. 22 Issue 1, p20, 1 p.

Record details

Natalizumab approved for multiple sclerosis

• Source: WHO Drug Information. Wntr, 2005, Vol. 19 Issue 1, p32, 1 p.

Record details

Natalizumab for moderateto- severe Crohn disease.

Subjects: THERAPEUTIC use of monoclonal antibodies; INFLAMMATORY bowel disease treatment; MULTIPLE sclerosis treatmentUNITED States

• Source: WHO Drug Information. 2008, Vol. 22 Issue 1, p20-20. 1/2p.

Record details

Natalizumab: progressive multifocal leukoencephalopathy.

Subjects: PROGRESSIVE multifocal leukoencephalopathy; MONOCLONAL antibodies; DISEASE risk factors

• Source: WHO Drug Information. Jan2012, Vol. 26 Issue 1, p32-33. 2p.

Record details

Known risks.

Subjects: ANTICONVULSANTS; DRUG interactions; METHYLPHENIDATE

• Source: WHO Drug Information. 2016, Vol. 30 Issue 1, p48-51. 4p.

Record details

ATC/DDD Classification (Final).

Subjects: DRUG dosage; WORLD Health Organization; DRUGS

• Source: WHO Drug Information. 2023, Vol. 37 Issue 2, p312-316. 5p.

Record details